• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿仑膦酸钠联合阿托伐他汀治疗糖尿病性骨质疏松症的疗效及安全性的 Meta 分析。

Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.

机构信息

Department of Spine Surgery, China-Japan Friendship Hospital, Beijing 100029, China.

Department of Orthopedics, Peking University International Hospital, Beijing 102206, China.

出版信息

Biomed Res Int. 2022 Feb 7;2022:6747469. doi: 10.1155/2022/6747469. eCollection 2022.

DOI:10.1155/2022/6747469
PMID:35178452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8844385/
Abstract

OBJECTIVE

Diabetes is a chronic disease caused by defective insulin secretion in the body, resulting in metabolic abnormalities with persistent blood glucose elevation. Osteoporosis is the most common diabetes complication. The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus.

METHODS

Two researchers independently used PubMed, ScienceDirect, Cochrane Library, Wanfang Data, CNKI, and VIP databases to search for all relevant studies that met the inclusion criteria and used RevMan 5.3 and STATA 16.0 for data analysis.

RESULTS

Fourteen studies that met the inclusion criteria were selected, including 1456 patients. Among the data extracted in this meta-analysis, bone mineral density (BMD) was the primary outcome measurement, while total effective rate, VAS, osteoprotegerin (OPG), bone Gla protein (BGP), bone alkaline phosphatase (BAP), blood P and Ca, and adverse effects were secondary outcome measurements. Our results showed that alendronate combined with atorvastatin is more effective than alendronate alone, with higher BMD, OPG, BGP, and BAP, more significant pain relief, and fewer adverse events.

CONCLUSION

The results of this meta-analysis indicate that alendronate combined with atorvastatin is a better treatment for osteoporosis in diabetes mellitus, showing more effective and higher BMD and fewer adverse events than alendronate alone.

摘要

目的

糖尿病是一种由体内胰岛素分泌缺陷引起的慢性疾病，导致代谢异常，持续血糖升高。骨质疏松症是糖尿病最常见的并发症。本研究旨在对阿仑膦酸钠联合阿托伐他汀与单独使用阿仑膦酸钠治疗糖尿病性骨质疏松症的效果进行 meta 分析。

方法

两名研究人员独立使用 PubMed、ScienceDirect、Cochrane Library、万方数据、中国知网和维普数据库搜索符合纳入标准的所有相关研究，并使用 RevMan 5.3 和 STATA 16.0 进行数据分析。

结果

共纳入 14 项符合纳入标准的研究，共 1456 例患者。在这项 meta 分析中提取的数据中，骨密度（BMD）是主要结局测量指标，而总有效率、VAS、骨保护素（OPG）、骨钙蛋白（BGP）、骨碱性磷酸酶（BAP）、血 P 和 Ca 以及不良反应是次要结局测量指标。结果显示，阿仑膦酸钠联合阿托伐他汀比单独使用阿仑膦酸钠更有效，BMD、OPG、BGP 和 BAP 更高，疼痛缓解更显著，不良反应更少。

结论

这项 meta 分析的结果表明，阿仑膦酸钠联合阿托伐他汀是治疗糖尿病性骨质疏松症的一种更好的方法，与单独使用阿仑膦酸钠相比，疗效更显著，BMD 更高，不良反应更少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/13c749e9fbd4/BMRI2022-6747469.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/bf1fd15340f4/BMRI2022-6747469.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/5e48c4076119/BMRI2022-6747469.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/ed69dcdff80a/BMRI2022-6747469.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/55b71c70baa9/BMRI2022-6747469.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/45cb9265b8e1/BMRI2022-6747469.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/11f8040f3ab4/BMRI2022-6747469.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/3f676aaf0d13/BMRI2022-6747469.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/6b5e6ceb1d87/BMRI2022-6747469.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/ef75ae6c318f/BMRI2022-6747469.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/0704dab120ff/BMRI2022-6747469.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/13c749e9fbd4/BMRI2022-6747469.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/bf1fd15340f4/BMRI2022-6747469.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/5e48c4076119/BMRI2022-6747469.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/ed69dcdff80a/BMRI2022-6747469.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/55b71c70baa9/BMRI2022-6747469.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/45cb9265b8e1/BMRI2022-6747469.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/11f8040f3ab4/BMRI2022-6747469.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/3f676aaf0d13/BMRI2022-6747469.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/6b5e6ceb1d87/BMRI2022-6747469.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/ef75ae6c318f/BMRI2022-6747469.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/0704dab120ff/BMRI2022-6747469.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441b/8844385/13c749e9fbd4/BMRI2022-6747469.011.jpg

相似文献

1
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.阿仑膦酸钠联合阿托伐他汀治疗糖尿病性骨质疏松症的疗效及安全性的 Meta 分析。
Biomed Res Int. 2022 Feb 7;2022:6747469. doi: 10.1155/2022/6747469. eCollection 2022.
2
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.阿仑膦酸盐和MK-677（一种生长激素促分泌素）单独及联合使用对绝经后骨质疏松症女性骨转换标志物和骨矿物质密度的影响。
J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25. doi: 10.1210/jcem.86.3.7294.
3
Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.评价绝经后骨质疏松症妇女应用阿仑膦酸钠治疗 1 年后的骨重建参数。
Bosn J Basic Med Sci. 2011 Feb;11(1):41-5. doi: 10.17305/bjbms.2011.2622.
4
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.阿仑膦酸盐和利塞膦酸盐对绝经后骨质疏松症患者骨密度及骨转换标志物影响的比较
Rheumatol Int. 2006 Jan;26(3):195-200. doi: 10.1007/s00296-004-0544-z. Epub 2004 Dec 2.
5
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.接受糖皮质激素治疗的类风湿关节炎患者骨质疏松症的治疗：阿仑膦酸钠与鼻用鲑鱼降钙素的比较。
Rheumatol Int. 2005 Nov;26(1):21-9. doi: 10.1007/s00296-004-0496-3. Epub 2005 Feb 2.
6
Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis.姜黄素与阿仑膦酸钠联合治疗可调节绝经后骨质疏松症女性的骨转换标志物并提高骨密度。
Arch Endocrinol Metab. 2018 Aug;62(4):438-445. doi: 10.20945/2359-3997000000060.
7
Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.阿仑膦酸钠治疗对绝经后骨质疏松症妇女血清护骨素和核因子κB 受体激活剂总量的影响。
Menopause. 2010 Jan-Feb;17(1):140-4. doi: 10.1097/gme.0b013e3181ac0cc1.
8
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.口服阿仑膦酸钠对老年骨质疏松症合并轻度原发性甲状旁腺功能亢进患者的影响。
J Bone Miner Res. 2001 Jan;16(1):113-9. doi: 10.1359/jbmr.2001.16.1.113.
9
Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.阿仑膦酸钠对接受长期重组人生长激素替代治疗的成年生长激素（GH）缺乏型骨质疏松症患者的额外有益作用：一项随机对照试验。
J Clin Endocrinol Metab. 2001 Jul;86(7):3079-85. doi: 10.1210/jcem.86.7.7669.
10
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.在双膦酸盐治疗的骨质疏松症患者中，核因子κB受体活化因子配体/骨保护素系统的变化与骨密度的变化相关。
Osteoporos Int. 2006;17(5):693-703. doi: 10.1007/s00198-005-0035-4. Epub 2006 Jan 25.

引用本文的文献

1
Efficacy of Statins in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis.他汀类药物在绝经后骨质疏松症中的疗效：一项系统评价和荟萃分析。
Cureus. 2025 Jun 20;17(6):e86425. doi: 10.7759/cureus.86425. eCollection 2025 Jun.
2
Potential Benefits of Adding Alendronate, Celecoxib, Itraconazole, Ramelteon, and Simvastatin to Endometrial Cancer Treatment: The EC5 Regimen.在子宫内膜癌治疗中添加阿仑膦酸钠、塞来昔布、伊曲康唑、雷美替胺和辛伐他汀的潜在益处：EC5方案
Curr Issues Mol Biol. 2025 Feb 26;47(3):153. doi: 10.3390/cimb47030153.
3
Trabecular Bone Score (TBS) in Individuals with Type 2 Diabetes Mellitus: An Updated Review.

本文引用的文献

1
The effects of alendronate treatment in the diagnosis and management of proximal femur osteoporosis: A real-life scenario.阿仑膦酸钠治疗在股骨近端骨质疏松症诊断和管理中的作用：真实案例。
Pak J Pharm Sci. 2021 Jul;34(4):1393-1396.
2
The Efficacy and Safety of Chinese Herbal Medicine Xianling Gubao Capsule Combined With Alendronate in the Treatment of Primary Osteoporosis: A Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials.中药仙灵骨葆胶囊联合阿仑膦酸钠治疗原发性骨质疏松症的疗效与安全性：一项对20项随机对照试验的系统评价和Meta分析
Front Pharmacol. 2021 Jul 16;12:695832. doi: 10.3389/fphar.2021.695832. eCollection 2021.
3
2型糖尿病患者的小梁骨评分（TBS）：最新综述
J Clin Med. 2023 Nov 29;12(23):7399. doi: 10.3390/jcm12237399.
4
Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures.阿仑膦酸钠联合鲑鱼降钙素对骨质疏松性骨折患者术后骨痛的影响。
Biomed Res Int. 2022 Sep 7;2022:1213278. doi: 10.1155/2022/1213278. eCollection 2022.
Fractures and Osteoporosis in Patients With Diabetes With Charcot Foot.
糖尿病性夏科足患者的骨折和骨质疏松症。
Diabetes Care. 2021 Sep;44(9):2033-2038. doi: 10.2337/dc21-0369. Epub 2021 Jul 27.
4
Diabetes and Osteoporosis: Part I, Epidemiology and Pathophysiology.糖尿病与骨质疏松症：第一部分，流行病学与病理生理学
Endocrinol Metab Clin North Am. 2021 Jun;50(2):275-285. doi: 10.1016/j.ecl.2021.03.005. Epub 2021 Apr 28.
5
Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study.他汀类药物对新发骨质疏松症风险的长期影响：一项全国范围内基于人群的队列研究。
PLoS One. 2018 May 3;13(5):e0196713. doi: 10.1371/journal.pone.0196713. eCollection 2018.
6
Diabetes and osteoporosis: Action of gastrointestinal hormones on the bone.糖尿病与骨质疏松症：胃肠激素对骨骼的作用
Rev Clin Esp (Barc). 2013 Aug-Sep;213(6):293-7. doi: 10.1016/j.rce.2013.01.014. Epub 2013 Mar 29.
7
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.Cochrane 协作网评估随机试验偏倚风险的工具。
BMJ. 2011 Oct 18;343:d5928. doi: 10.1136/bmj.d5928.
8
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.系统评价与Meta分析优先报告条目：PRISMA声明
PLoS Med. 2009 Jul 21;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.